Basilea Pharmaceutica (XSWX:BSLN) Scaled Net Operating Assets: 0.23 (As of Dec. 2025)


XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
62 GF Score
Price CHF52.40
GF Value CHF57.38
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Scaled Net Operating Assets?

Basilea Pharmaceutica XSWX:BSLN +0.96% 62 Scaled Net Operating Assets is 0.23 as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 62/100 and a GF Value™ of CHF57.38 (Fairly Valued). The stock has 2 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Basilea Pharmaceutica's operating assets for the quarter that ended in Dec. 2025 was CHF122.2 Mil. Basilea Pharmaceutica's operating liabilities for the quarter that ended in Dec. 2025 was CHF64.8 Mil. Basilea Pharmaceutica's Total Assets for the quarter that ended in Jun. 2025 was CHF248.8 Mil. Therefore, Basilea Pharmaceutica's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.23.

Basilea Pharmaceutica Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Scaled Net Operating Assets Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.33 0.27 0.42 0.22

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.38 0.38 0.28 0.23

XSWX:BSLN vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Basilea Pharmaceutica's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Basilea Pharmaceutica Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Scaled Net Operating Assets falls into.


XSWX:BSLN
62GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Basilea Pharmaceutica's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(122.199-64.841)/257.764
=0.22

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=281.999 - 159.8
=122.199

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=154.058 - 87.155 - 2.062
=64.841

Basilea Pharmaceutica's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Jun. 2025 )
=(122.199-64.841)/248.847
=0.23

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=281.999 - 159.8
=122.199

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=154.058 - 87.155 - 2.062
=64.841

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.23 mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Scaled Net Operating Assets of 0.23 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Scaled Net Operating Assets too high?
Basilea Pharmaceutica's current Scaled Net Operating Assets is 0.23. Overall, Basilea Pharmaceutica has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Scaled Net Operating Assets compare to VRTX and REGN?
Basilea Pharmaceutica's Scaled Net Operating Assets of 0.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Scaled Net Operating Assets is 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.38, compared to a current price of CHF52.40 — trading 8.7% below its estimated fair value. The current Scaled Net Operating Assets is 0.23. Basilea Pharmaceutica's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Scaled Net Operating Assets is 0.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF52.40 is trading 8.7% below its estimated GF Value™ of CHF57.38. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

  • Scaled Net Operating Assets: 0.23
  • GF Value™: CHF57.38 vs. price of CHF52.40 (8.7% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
62GF Score

Get the complete analysis for XSWX:BSLN

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF52.40
Price
CHF57.38
GF Value